Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Mycophenolate Mofetil

FDA-approved product (capsule, oral), marketed as Cellcept, Mycophenolate Mofetil, Myhibbin and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Mycophenolate Mofetil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Delayed Graft Function
  • Immune system disease
  • Multiple sclerosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective immunosuppressants
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae32.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Mycophenolate Mofetil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Mycophenolate Mofetil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

    NCT07352566 · start 2026-08-01

    Registered record
    Registry ID
    NCT07352566
    Conditions
    Psoriasis; Atopic Dermatitis
    Interventions
    In situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene; Tapinarof; Crisaborole; Tacrolimus; Adalimumab; Etanercept; Certolizumab; Infliximab; Secukinumab; Ixekizumab; Apremilast; Risankizumab; Ustekinumab; Hydroxychloroquine; Methotrexate; Mycophenolate; Azathioprine; Chloroquine; Cyclosporine; Tofacitinib; Deucravacitinib; Dupilumab; Tralokinumab; Guselkumab; Tildrakizumab; Baractinib; Abrocitinib; Upadacitinib; Lebrikizumab; Nemolizumab; Ruxolitinib; Bimekizumab; Roflumilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2030-06-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Atopic Dermatitis
    InterventionIn situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene +32 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML

    NCT07572695 · start 2026-04-30

    Registered record
    Registry ID
    NCT07572695
    Conditions
    Acute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia; AML, Relapsed/Refractory
    Interventions
    Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT); Post-transplant Maintenance Therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-04-30
    Completion
    2028-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia; AML, Relapsed/Refractory
    InterventionHaploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT); Post-transplant Maintenance Therapy
    PhaseNot recorded
    Registry statusNot yet recruiting

  • A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

    NCT07412470 · start 2026-03-13

    Registered record
    Registry ID
    NCT07412470
    Conditions
    Kidney Transplant Rejection
    Interventions
    Frexalimab; Frexalimab; Tacrolimus; rabbit anti-thymocyte globulin; mycophenolate mofetil; mycophenolate sodium; methylprednisolone; prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-03-13
    Completion
    2033-08-15
    Enrolment
    526

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant Rejection
    InterventionFrexalimab; Frexalimab; Tacrolimus; rabbit anti-thymocyte globulin +4 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis

    NCT07080125 · start 2025-06-17

    Registered record
    Registry ID
    NCT07080125
    Conditions
    Interstitial Lung Diseases; Systemic Sclerosis Associated Interstitial Lung Disease
    Interventions
    Ofev®
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-06-17
    Completion
    2033-12-31
    Enrolment
    2,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInterstitial Lung Diseases; Systemic Sclerosis Associated Interstitial Lung Disease
    InterventionOfev®
    PhaseNot recorded
    Registry statusActive not recruiting

  • Phase 2 Study of Rapcabtagene Autoleucel in Myositis

    NCT06665256 · start 2024-12-17

    Registered record
    Registry ID
    NCT06665256
    Conditions
    Idiopathic Inflammatory Myopathies
    Interventions
    Rapcabtagene autoleucel; Active Comparator Option
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2024-12-17
    Completion
    2032-11-29
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Inflammatory Myopathies
    InterventionRapcabtagene autoleucel; Active Comparator Option
    PhasePhase 2
    Registry statusActive not recruiting

  • Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura

    NCT05951517 · start 2023-01-01

    Registered record
    Registry ID
    NCT05951517
    Conditions
    Henoch-Schönlein Purpura; Gastrointestinal Injury; Mycophenolate Mofetil
    Interventions
    MMF
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-01-01
    Completion
    2026-12-31
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHenoch-Schönlein Purpura; Gastrointestinal Injury; Mycophenolate Mofetil
    InterventionMMF
    PhaseNot applicable
    Registry statusRecruiting

  • Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular Carcinoma

    NCT04168944 · start 2019-11

    Registered record
    Registry ID
    NCT04168944
    Conditions
    Hepatocellular Carcinoma
    Interventions
    Lenvatinib; Placebo; Immunosuppressive regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2019-11
    Completion
    2022-09
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatocellular Carcinoma
    InterventionLenvatinib; Placebo; Immunosuppressive regimen
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis

    NCT03920059 · start 2019-08-20

    Registered record
    Registry ID
    NCT03920059
    Conditions
    Lupus Nephritis
    Interventions
    Mycophenolate Mofetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-08-20
    Completion
    2020-01-30
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLupus Nephritis
    InterventionMycophenolate Mofetil
    PhasePhase 4
    Registry statusTerminated

  • Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis

    NCT03844061 · start 2019-07-29

    Registered record
    Registry ID
    NCT03844061
    Conditions
    Systemic Sclerosis
    Interventions
    Belimumab; Rituximab; Placebo Subcutaneous Injection; Placebo Infusion; MMF
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2019-07-29
    Completion
    2026-06-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Sclerosis
    InterventionBelimumab; Rituximab; Placebo Subcutaneous Injection; Placebo Infusion +1 more
    PhasePhase 2
    Registry statusRecruiting

  • CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid

    NCT03492255 · start 2018-04-12

    Registered record
    Registry ID
    NCT03492255
    Conditions
    Systemic Lupus Erythematosus (SLE)
    Interventions
    Cyclophosphamide; Methylprednisolone; Prednisone; Mycophenolate Mofetil
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2018-04-12
    Completion
    2021-07-02
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Lupus Erythematosus (SLE)
    InterventionCyclophosphamide; Methylprednisolone; Prednisone; Mycophenolate Mofetil
    PhaseNot applicable
    Registry statusTerminated

  • Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.

    NCT03216967 · start 2018-01-15

    Registered record
    Registry ID
    NCT03216967
    Conditions
    BK Virus Nephropathy After Kidney Transplantation
    Interventions
    everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-15
    Completion
    2024-08-01
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBK Virus Nephropathy After Kidney Transplantation
    Interventioneverolimus
    PhasePhase 4
    Registry statusCompleted

  • Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)

    NCT03263559 · start 2017-10-03

    Registered record
    Registry ID
    NCT03263559
    Conditions
    Sickle Cell Disease
    Interventions
    Haploidentical Bone Marrow Transplantation; Hydroxyurea; Rabbit-ATG; Thiotepa; Fludarabine; Cyclophosphamide; Total Body Irradiation; Mesna
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-10-03
    Completion
    2025-01-29
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease
    InterventionHaploidentical Bone Marrow Transplantation; Hydroxyurea; Rabbit-ATG; Thiotepa +4 more
    PhasePhase 2
    Registry statusCompleted

  • Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

    NCT03478215 · start 2016-12

    Registered record
    Registry ID
    NCT03478215
    Conditions
    Renal Transplantation; Mesenchymal Stem Cells
    Interventions
    Mesenchymal Stromal Stem Cells (MSCs) Infusion; Normal Saline (Placebo) Infusion
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2016-12
    Completion
    2026-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Transplantation; Mesenchymal Stem Cells
    InterventionMesenchymal Stromal Stem Cells (MSCs) Infusion; Normal Saline (Placebo) Infusion
    PhasePhase 2
    Registry statusActive not recruiting

  • Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.

    NCT03596970 · start 2015-09

    Registered record
    Registry ID
    NCT03596970
    Conditions
    Liver Transplantation
    Interventions
    TAC withdrawal; Everolimus with reduced TAC
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2015-09
    Completion
    2020-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation
    InterventionTAC withdrawal; Everolimus with reduced TAC
    PhasePhase 3
    Registry statusWithdrawn

  • Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen

    NCT02199041 · start 2014-07-11

    Registered record
    Registry ID
    NCT02199041
    Conditions
    Hematological Malignancies
    Interventions
    Cyclophosphamide; Thiotepa; Fludarabine; Melphalan; Mesna; G-CSF; Mycophenolate mofetil; Tacrolimus; Methylprednisolone; Total lymphoid irradiation; Lymphocyte infusions; CliniMACS
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-07-11
    Completion
    2017-05-23
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematological Malignancies
    InterventionCyclophosphamide; Thiotepa; Fludarabine; Melphalan +8 more
    PhasePhase 2
    Registry statusTerminated